Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Side-by-side COA corpus data for the 12 peptides removed from FDA Category 2 in April 2026 — BPC-157, TB-500, CJC-1295, Ipamorelin, and more. All figures are computed directly from lab-issued Certificates of Analysis indexed by Disclosed Labs. No editorial claims.
FDA advisory meeting: July 23–24, 2026. The PCAC reviews nominations and makes recommendations — the FDA issues any final rule later. None of these peptides are currently on the authorized Category 1 (503A) list. Track status →
| Peptide | COAs | Avg Purity | Vendors | Labs |
|---|---|---|---|---|
| BPC-157 Healing / Recovery | 334 | 99.3% | 49 | 16 |
| GHK-Cu Skin / Copper Peptide | 215 | 99.6% | 52 | 17 |
| Tesamorelin Growth Hormone Releasing | 175 | 99.5% | 44 | 14 |
| Thymosin Beta-4 (TB-500) Healing / Recovery | 170 |
Disclosed Labs' verified corpus contains 1,410 Certificates of Analysis spanning all 12 peptides removed from FDA Category 2 in April 2026. The most-tested peptide is BPC-157 with 334 COAs from 49 vendors. COAs include HPLC purity, lab identity, and (where performed) endotoxin and sterility results.
Across the 11 peptides with sufficient COA corpus data, the average reported HPLC purity is 99.4%. Individual peptide averages vary — see the per-peptide breakdown in the table on this page. Purity figures come from third-party HPLC analysis in lab-issued Certificates of Analysis indexed by Disclosed Labs. Values outside 50–100% are excluded as unit misreads.
Among the most frequently appearing labs for these peptides in Disclosed's corpus: ILS Labs, Ethos Analytics. Total lab coverage is broader — the table above shows the full lab count per peptide; see individual peptide testing pages for the complete list. Lab grades reflect Disclosed's credibility scoring — purity distribution, safety panel breadth, and verification engagement.
No. As of mid-2026, none of the 12 peptides are officially on the FDA Category 1 (503A) list. In April 2026, the FDA removed them from Category 2 (the significant-safety-risk list) — placing them in a regulatory gray zone. The FDA's Pharmacy Compounding Advisory Committee (PCAC) meets July 23–24, 2026 to review nominations and make recommendations; the FDA issues any final rule later. The testing data on this page reflects research-channel COA coverage, not pharmacy-grade compounding authorization.
| 99.3% |
| 41 |
| 16 |
| Ipamorelin Growth Hormone Secretagogue | 153 | 99.7% | 36 | 17 |
| CJC-1295 Growth Hormone Secretagogue | 115 | 98.8% | 29 | 12 |
| Selank Anxiolytic / Nootropic | 81 | 99.6% | 34 | 18 |
| Sermorelin Growth Hormone Releasing | 72 | 99.4% | 29 | 10 |
| DSIP Sleep / Neuropeptide | 69 | 99.4% | 30 | 14 |
| GHRP-2 Growth Hormone Secretagogue | 13 | 99.3% | 8 | 6 |
| GHRP-6 Growth Hormone Secretagogue | 13 | 99.4% | 9 | 4 |
| GHK Skin / Wound Healing | — | no data | — | — |
COA counts are from Disclosed's verified corpus (PUBLIC+EXTRACTED). Purity = average HPLC % across verified COAs (50–100% range). Vendor/lab counts reflect unique entities with at least one indexed COA.
Disclosed Labs indexes publicly available Certificates of Analysis from research peptide vendors and direct lab submissions. COAs are verified for authenticity, then HPLC purity figures, lab identity, lot numbers, and safety-panel results are extracted. Only COAs from verified labs with parseable HPLC data are included in purity averages. The corpus is updated continuously as new COAs are published.
Disclosed Labs